Renovaro Biosciences (RENB) has released an update to notify the public and investors about corporate charter and bylaws modifications.
Renovaro Biosciences Inc., in a move to expand its financing options, has significantly increased its share capital, with authorized shares jumping from 110 million to 360 million and common stock shares rising from 100 million to 350 million. This change, effective immediately, received shareholder approval on January 25, 2024, and marks a strategic shift for the company, potentially signaling growth initiatives or plans for future investment opportunities.
For further insights into RENB corporate activity, check out TipRanks’ Insiders Trading Activity page.
For a comprehensive understanding of the announcement, you can read the full document here.
